FdaApplication
NDA 213871
Identifiers
- fda_app_no: NDA213871
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2022-01-14 |
Revenue by product
CIBINQO
| Period | Revenue |
|---|---|
| Q2 2026 | $94.0M |
| Q1 2026 | $76.0M |
| Q3 2025 | $79.0M |
| Q2 2025 | $69.0M |
| Q1 2025 | $58.0M |
| Q3 2024 | $63.0M |
| Q2 2024 | $47.0M |
| Q1 2024 | $42.0M |
| Q4 2023 | $37.0M |
| Q3 2023 | $37.0M |
| Q2 2023 | $38.0M |
| Q1 2023 | $16.0M |
| Q4 2022 | $10.0M |
| Q3 2022 | $11.0M |
| Q2 2022 | $1.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (3)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| CIBINQO | ABROCITINIB | 200MG | TABLET;ORAL |
| CIBINQO | ABROCITINIB | 100MG | TABLET;ORAL |
| CIBINQO | ABROCITINIB | 50MG | TABLET;ORAL |
3 products